二聚体FcγR胞外域检测肝素诱导的血小板减少症中的致病性抗血小板因子4-肝素抗体
本研究用二聚体重组可溶性FcγRIIa胞外域探针检测27例疑似肝素诱导的血小板减少症(HIT)患者血浆中的致病性抗血小板因子4(PF4)-肝素抗体,并与PF4-肝素IgG ELISA、HemosIL AcuStar HIT IgG特异性试验及5-羟色胺释放试验(SRA)比较。该新型试验无假阳性,正确分类93%的疑似HIT患者,其中2例HIT患者被判为假阴性。作者认为该无细胞、基于功能的二聚体rsFcγRIIa试验简便、简单且可能预测HIT,特异性优于IgG ELISA,与AcuStar HIT IgG特异性试验强相关,值得在更大患者队列中进一步评估其识别HIT的潜力。
要点
- 二聚体rsFcγRIIa试验无假阳性,并排除了4份IgG ELISA阳性样本。
- 该试验正确分类93%的疑似HIT患者,2例HIT患者被判为假阴性。
- 该试验特异性优于IgG ELISA,与AcuStar HIT IgG特异性试验强相关。
核心结论
- 作者认为无细胞、基于功能的二聚体rsFcγRIIa试验便捷、简单且可能预测HIT。
- 该试验特异性优于IgG ELISA,与AcuStar HIT IgG特异性试验强相关,值得在更大患者队列中进一步评估其识别HIT的潜力。
研究设计与样本
- 本研究检测27例疑似HIT患者血浆中的致病性抗PF4-肝素抗体,使用新型二聚体FcγRIIa胞外域探针结合试验。
- 同时使用PF4-肝素IgG ELISA、HemosIL AcuStar HIT IgG特异性试验和5-羟色胺释放试验(SRA)进行检测。
主要发现
- 二聚体rsFcγRIIa试验无假阳性,并排除了4份IgG ELISA阳性样本。
- 在该小患者队列中,新型试验正确分类93%的疑似HIT患者,其中2例HIT患者被判为假阴性。
- IgG ELISA出现4例假阳性。
- 二聚体rsFcγRIIa结合与HIT发生特异性相关。
关键数值与推荐
- 二聚体rsFcγRIIa试验正确分类93%的疑似HIT患者。
- IgG ELISA出现4例假阳性。
- 二聚体rsFcγRIIa试验排除了4份IgG ELISA阳性样本。
临床怎么用
- 作者认为二聚体rsFcγRIIa试验便捷、简单且可能预测HIT,值得在更大患者队列中进一步评估。
局限性
- 该研究为小患者队列,2例HIT患者被判为假阴性。
- 作者指出需在更大患者队列中进一步评估该试验识别HIT的潜力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Essentials FcγRIIa mediates life-threatening heparin-induced thrombocytopenia (HIT). Most anti-platelet factor (PF)4-heparin IgGs are not pathogenic so diagnosis of HIT is challenging. Dimeric rsFcγRIIa was used to quantify receptor-binding activity of anti-PF4-heparin antibodies. Dimeric rsFcγRIIa binding specifically correlated with occurrence of HIT. SUMMARY: Background Heparin-induced thrombocytopenia (HIT) is a major and potentially fatal consequence of antibodies produced against platelet factor 4 (PF4)-heparin complexes following heparin exposure. Not all anti-PF4-heparin antibodies are pathogenic, so overdiagnosis can occur, with resulting inappropriate use of alternative anticoagulation therapies that have associated risks of bleeding. However, definitive platelet functional assays are not widely available for routine analysis. Objectives To assess the utility of dimeric recombinant soluble FcγRIIa (rsFcγRIIa) ectodomains for detecting HIT antibodies. Patients/Methods Plasma from 27 suspected HIT patients were tested for pathogenic anti-PF4-heparin antibodies by binding of a novel dimeric FcγRIIa ectodomain probe. Plasmas were also tested by the use of PF4-heparin IgG ELISA, the HemosIL AcuStar HIT IgG-specific assay, and a serotonin release assay (SRA). Results The dimeric rsFcγRIIa test produced no false positives and excluded four samples that were positive by IgG ELISA. In this small patient cohort, the novel assay correctly assigned 93% of the suspected HIT patients, with two of the HIT patients being scored as false negatives. The improved discrimination of the novel assay over the IgG ELISA, which scored four false positives, supports the mechanistic interpretation that binding of dimeric rsFcγRIIa detects pairs of closely spaced IgG antibodies in PF4-heparin immune complexes. Conclusions This study found the cell-free, function-based dimeric rsFcγRIIa assay to be convenient, simple, and potentially predictive of HIT. The assay had improved specificity over the IgG ELISA, and correlated strongly with the AcuStar HIT IgG-specific assay, warranting further evaluation of its potential to identify HIT in larger patient cohorts.
引用
- Wines BD, Tan CW, Duncan E, et al. Dimeric FcγR ectodomains detect pathogenic anti-platelet factor 4-heparin antibodies in heparin-induced thromobocytopenia. J Thromb Haemost. 2018. PMID: 30269432. doi:10.1111/jth.14306
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。